Adam Sperling, MD, PhD

Adam Sperling, MD, PhD, discusses future research with CAR T-cell therapy in multiple myeloma.

Adam Sperling, MD, PhD, discusses managing CAR T-cell therapy–related toxicities in multiple myeloma.

Adam Sperling, MD, PhD, discusses future research directions with idecabtagene vicleucel for the treatment of patients with multiple myeloma.

Adam Sperling, MD, PhD, discusses the rationale to evaluate cellular therapy in multiple myeloma.